Therapeutic Parenteral Drug Administration (Single or Two or More Administrations)
Therapeutic parenteral drug administration may be indicated to enhance healing of surgical procedures, or reduce pain and/or risk of infection. Medications include antibiotics, steroids or anti-inflammatory drugs.

Infiltration of Sustained Release Therapeutic Drug (Single or Multiple Sites)
Infiltration of sustained release therapeutic drug (e.g., Exparel®) is not indicated due to insufficient evidence of efficacy.

Drugs or Medicaments Dispensed in the Office for Home Use
Dispensing of drugs may be indicated to enhance healing of surgical procedures, or reduce pain and/or risk of infection. These include, but are not limited to oral antibiotics, oral analgesics, and topical fluoride.

Coverage Exclusions
- Procedures that are considered to be Experimental, Investigational or Unproven

Definitions
Experimental, Investigational or Unproven Services: Medical, dental, surgical, diagnostic, or other health care services, technologies, supplies, treatments, procedures, drug therapies or devices that, at the time of determination regarding coverage in a particular case, is determined to be:
- Not approved by the U.S. Food and Drug Administration (FDA) to be lawfully marketed for the proposed use and not identified in the American Hospital Formulary Service or the United States Pharmacopoeia Dispensing Information as appropriate for the proposed use; or
- Subject to review and approval by any institutional review board for the proposed use; or
- The subject of an ongoing clinical trial that meets the definition of a Phase 1, 2 or 3 clinical trial set forth in the FDA regulations, regardless of whether the trial is actually subject to FDA oversight; or
- Not demonstrated through prevailing peer-reviewed professional literature to be safe and effective for treating or diagnosing the condition or illness for which its use is proposed; or
- Pharmacological regimens not accepted by the American Dental Association (ADA) Council on Dental Therapeutics

Parenteral: A technique of administration in which the drug bypasses the gastrointestinal (GI) tract [i.e., intramuscular (IM), intravenous (IV), intranasal (IN), submucosal (SM), subcutaneous (SC), intraosseous (IO)].
Parenteral administration of drugs is any technique in which the route of administration bypasses the gastrointestinal tract. These routes include, but are not limited to, intravenous administration, intramuscular and subcutaneous injections and the use of medication patches and nasal sprays. There are many medicaments that may be given to a patient in the dental office for use at home and these include prescription strength toothpastes and mouth rinses, as well as antibiotics and pain medication. Exparel® is a sustained release long acting form of bupivacaine. It can reduce or eliminate the need for opioids in the treatment of post-surgical pain; however the clinical significance of opioid reduction has not been established in clinical trials (Noviasky). The evidence regarding its benefits for use in dentistry and oral surgery is limited.

Gorecki et al. (2018) conducted a prospective, randomized, double-blind, placebo-controlled, parallel-group phase II single-center (ClinicalTrials.gov NCT01706588) to evaluate the efficacy, safety, and local tolerability of diclofenac HPβCD administered as a local submucosal injection prior to lower third molar surgery. Seventy-five patients requiring mandibular third molar surgery were randomized into 1 of 5 groups: 5 mg/1 mL diclofenac HPβCD, 12.5 mg/1 mL diclofenac HPβCD, 25 mg/1 mL diclofenac HPβCD, 50 mg/1 mL diclofenac HPβCD, or 1 mL placebo. The study drug was injected into the mucosal tissue surrounding the surgical site prior to surgery following achievement of local anesthesia. The primary outcome measure was the area under the curve (AUC) of cumulative pain scores from end of surgery to 6 h postsurgery. This demonstrated a global treatment effect between the active groups and placebo, hence confirming the study drug's efficacy (P = 0.0126). Secondary outcome measures included the time until onset of pain and the time until patients required rescue medication, both showing statistical significance of the study drug compared to placebo. The time until rescue medication ranged between 7.8 h (for 25 mg/1 mL diclofenac HPβCD) and 16 h (for 50 mg/1 mL diclofenac HPβCD). The 5-mg/1-mL solution appeared superior to the 12.5-mg/1-mL and 25-mg/1-mL solutions (time until rescue medication = 12.44 h). A total of 14% of patients experienced minor adverse drug reactions (ADRs), of which 2 cases demonstrated flap necrosis. These resolved without further intervention. The authors concluded that these results overall indicate efficacy, safety, and relative tolerability of diclofenac HPβCD used locally as a submucosal injection prior to third molar surgery.

Al-Dajani (2017) conducted a triple-blinded split-mouth randomized controlled clinical trial of 32 patients who underwent randomized bilateral extractions of impacted mandibular third molars during 2 consecutive sessions. Each patient was given a single-dose intramuscular injection of dexamethasone (0.1 mg/kg) preoperatively in 1 session and a placebo in the other session. Data were collected daily for 7 postoperative days, and 14 patient-centered outcomes were interpreted. The results showed that when administered dexamethasone, patients reported less pain, took fewer analgesics, reported less swelling, had less difficulty in eating and in enjoying food, had less difficulty in speech, and had less disruption of daily activities. The differences between the 2 conditions in bleeding, malaise, and sleep disturbance were not significant. The author concluded that prophylactic dexamethasone administered intramuscularly before third molar surgery can be recommended as a safe and effective strategy for decreasing pain and discomfort and enhancing oral functions and daily activities, unless contraindicated.

Arora et al. (2014) conducted a prospective randomized double-blind placebo-controlled clinical trial to evaluate whether postoperative combined amoxicillin and clavulanic acid in mandibular third molar extraction is effective in preventing inflammatory complications. Two bilaterally similar impacted mandibular third molars per head in 48 patients were randomly assigned to two treatment groups (Group I and Group II). Each patient served as his/her own control. Each patient received 625 mg of combined amoxicillin and clavulanic acid 1 h before surgery. In the case of

---

**APPLICABLE CODES**

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Clinical Policies and Coverage Guidelines may apply.

<table>
<thead>
<tr>
<th>CDT Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>D9610</td>
<td>Therapeutic parenteral drug, single administration</td>
</tr>
<tr>
<td>D9612</td>
<td>Therapeutic parenteral drugs, two or more administrations, different medications</td>
</tr>
<tr>
<td>D9613</td>
<td>Infiltration of sustained release therapeutic drug – single or multiple sites</td>
</tr>
<tr>
<td>D9630</td>
<td>Drugs or medicaments dispensed in the office for home use</td>
</tr>
</tbody>
</table>

**DESCRIPTION OF SERVICES**

Page 2 of 7

UnitedHealthcare Dental Clinical Policy

Proprietary Information of UnitedHealthcare. Copyright 2019 United HealthCare Services, Inc.
third molars belonging to Group I, 625 mg of combined amoxicillin and clavulanic acid TDS was continued for 3 days; in Group II, placebo was continued for 3 days. The patients were evaluated on the third and seventh postoperative days for signs of clinical infection and for microbial load evaluation. The data between the two groups were then statistically analyzed by the two-tailed Fisher’s exact test, with a 95% confidence interval. The results showed no statistically significant differences between the test group and the control group with regard to erythema, dehiscence, swelling, pain, trismus, and infection based on microbial load. The data were statistically significant for alveolar ostelitis, with the occurrence of alveolar ostelitis (14.58%) in the placebo group. The authors concluded postoperative antibiotics are recommended only for patients undergoing contaminated, long-duration surgery.

Chugh et al. (2017) conducted a randomized controlled trial to compare the effects of the preoperative submucosal administration of equivalent doses of two commonly used steroids on the known postoperative sequelae following third molar extractions: pain, swelling, and trismus. There were 60 subjects requiring the removal of impacted mandibular third molars with a similar difficulty index. The participants were allocated randomly to three groups: the placebo group received normal saline injection (control), while the 8mg dexamethasone group and 40mg methylprednisolone group received submucosal injections of these steroids preoperatively. Each participant was assessed for postoperative pain, swelling, and trismus, along with a subjective assessment of quality of life (QOL) through a structured questionnaire. The results showed that the participants administered dexamethasone showed significant reductions in pain and trismus compared to the control group. Submucosal injection of dexamethasone was found to be superior to methylprednisolone only in terms of the reduction in swelling. QOL was minimally affected in patients administered dexamethasone as compared to methylprednisolone and control subjects. The authors concluded that within this small patient population, the preoperative submucosal use of steroids can be considered an effective, safe, and simple therapeutic strategy to reduce swelling, pain, and trismus after the surgical removal of impacted mandibular third molars.

Arteagoitia et al (2016) Prophylactic use of amoxicillin and amoxicillin/clavulanic acid, although controversial, is common in routine clinical practice in third molar surgery. The authors conducted a systematic review and meta-analysis including double-blind placebo-controlled randomized clinical trials published up to June 2015 to investigate the efficacy of amoxicillin with or without clavulanic acid on the incidence of the in the prevention of infection and dry socket after third molar extraction. There were 10 papers included in the review. The results of this review showed that the prophylactic use of amoxicillin does not significantly reduce the risk of infection and/or dry socket after third molar extraction, however with amoxicillin/clavulanic acid, the risk decreases significantly. The authors concluded however, that considering the number needed to treat, low prevalence of infection, potential adverse reactions to antibiotics and lack of serious complications in placebo groups, the routine prescription of amoxicillin with or without clavulanic acid is not justified.

Ataoğlu et al (2008) conducted a study to evaluate the efficacy of antibiotic prophylaxis during removal of impacted third molars. 150 patients with impacted mandibular or maxillary third molars were divided randomly into three groups. The first was given amoxicillin 2g combined with clavulanic acid, orally daily for 5 days postoperatively; starting at the end of the operation. The second group was given the same drugs but the regimen started 5 days before the operation. The third was given no antibiotics. Pain, infection, swelling, alveolar ostelitis, and interincisal mouth opening (mm) were evaluated. There were no significant differences among the groups in the incidence of these complications. The authors concluded that routine prophylactic use of oral antibiotics in third molar surgery is not recommended.

Dietrich et al (2014). Diclofenac is an effective and well-tolerated nonsteroidal anti-inflammatory drug (NSAID) frequently used in the treatment of acute pain. Marketed formulations for parenteral administration usually contain 75 mg/3 mL of diclofenac sodium, which provide limited dosing flexibility, and are usually given intramuscularly. The authors conducted a randomized double blind trial to investigate the safety and efficacy of low dose subcutaneous (SC) diclofenac containing hydroxypropyl-β-cyclodextrin (HPβCD) as a solubility enhancer for the management of acute pain. In this study, patients developing moderate-to-severe pain after third molar extraction under local anesthesia were randomized to one of the 4 SC injections: 25, 50, or 75 mg diclofenac, or placebo. The pain intensity differences were measured at 1.5 hours post dose and showed was higher in all diclofenac-treated groups than the placebo group. The authors concluded that this SC delivery of diclofenac containing (HPβCD) is effective at 25 and 50 mg levels for relieving moderate to severe pain following third molar extraction.

Graziani et al (2006) conducted a split-mouth randomized double-masked clinical trial to study the effect of endo-alveolar and sub-mucosal administrations of dexamethasone sodium phosphate to prevent inflammatory sequelae after surgical removal of lower third molars. Forty-three patients underwent bilateral extractions of lower third molars and were randomly assigned to receive either dexamethasone 4 mg (group A) or 10 mg (group B) as endo-alveolar powder or 10 mg as sub-mucosal injection (group C) unilaterally. The contralateral site served as control and did not receive any steroid administration. Facial edema, trismus and pain perception were evaluated at the 2nd and 7th postoperative day. A multivariate analysis revealed that treatment and ostectomy time were both significantly positively associated with the degree of postoperative trismus and edema. Other baseline classification variables (e.g.,
molar classification) were also predictive of the degree of change in all clinical parameters. Test sites treated (any steroid application) showed greater reductions in all clinical parameters recorded compared to control. No statistically significant differences were observed between the three test groups. The authors concluded that both sub-mucosal and endo-alveolar administration of dexamethasone is effective in reducing postoperative sequelae of surgical removal of lower wisdom teeth.

Herrera-Briones FJ et al (2013) conducted a systematic literature review on the use of corticosteroids in third molar surgery. A systematic search of the literature was carried out in PubMed, Scopus, MEDLINE, and Cochrane using steroid and third molar as key words. 27 Randomized controlled trials and 1 meta-analysis were selected from among 72 articles identified, and included RCTs that compared perioperative steroids given in any formulation, dose, or route with either placebo or no treatment, and included patients of any age requiring the removal of one or more impacted third molars under local anesthesia, intravenous (IV) sedation, or general anesthesia. Articles were not restricted as a function of the method used to measure pain. The authors of this review concluded the evidence shows that the administration of corticosteroids improves the postoperative experience of patients and has a significant impact on trismus and inflammation. Greater effects appear to be achieved by using the parenteral route and by administering the corticosteroid before the surgery.

Mohan et al (2014) conducted a randomized, controlled clinical study to evaluate the role of antibiotics to prevent postoperative complications after routine periodontal surgery and also to determine whether their administration improved the surgical outcome. Forty-five systemically healthy patients with moderate to severe chronic periodontitis requiring flap surgery were enrolled in the study. They were randomly allocated to Amoxicillin, Doxycycline, and control groups. Surgical procedures were carried out with complete asepsis as per the protocol. Postoperative assessment of patient variables like swelling, pain, temperature, infection, ulceration, necrosis, and trismus was performed at intervals of 24 h, 48 h, 1 week, and 3 months. Changes in clinical parameters such as gingival index, plaque index, probing pocket depth, and clinical attachment level were also recorded. There was no incidence of postoperative infection in any of the patients. Patient variables were comparable in all the three groups. Though there was significant improvement in the periodontal parameters in all the groups, no statistically significant result was observed for any group over the others. The results of this study showed that when periodontal surgical procedures were performed following strict asepsis, the incidence of clinical infection was not significant among all the three groups, and also that antibiotic administration did not influence the outcome of surgery. Therefore, prophylactic antibiotics for patients who are otherwise healthy administered following routine periodontal surgery to prevent postoperative infection are unnecessary and have no demonstrable additional benefits.

**Exparel (Liposomal Bupivacaine)**

Iero et al. (2018) conducted a randomized, open-label trial to determine the efficacy and safety of an opioid-sparing postsurgical pain management protocol with or without local infiltration of liposomal bupivacaine for full-arch implant surgery (four or more implants to the maxilla and/or mandible to serve as anchors for dental prostheses). Patients scheduled to undergo full-arch implant surgery were randomly assigned to receive an opioid-sparing postsurgical pain management protocol with or without liposomal bupivacaine 266 mg at the end of surgery. All patients received infiltration with ≤ 40 mL lidocaine 2% with epinephrine at the beginning of surgery and bupivacaine 0.5% with epinephrine near the end of surgery and oral opioid or nonopioid analgesics (oxycodone 5 mg tablets or ibuprofen 600 mg), as needed, post surgically. Pain severity at the surgical site was assessed using a verbal 0 to 10 numeric rating scale (0 [no pain] to 10 [worst pain imaginable]). Patients separately assessed pain in their mandible and maxilla. Reports of treatment-emergent adverse events were collected. Sixty-nine patients were randomized to the liposomal bupivacaine 266 mg (n = 34) or control group (n = 35). At all time points post surgery for both the mandible and the maxilla, the liposomal bupivacaine group reported significantly less cumulative pain than the control group. At the conclusion of the 7-day follow-up, patients in the liposomal bupivacaine group experienced one-third less cumulative postsurgical pain than patients in the control group. Seventy-seven percent of patients in the liposomal bupivacaine group and 80% in the control group experienced a treatment-emergent adverse event. A higher percentage of patients in the liposomal bupivacaine versus control group reported itching (15% vs 9%) and constipation (38% vs 23%). The authors concluded that patients receiving an opioid-sparing postsurgical pain management protocol with liposomal bupivacaine 266 mg experienced a statistically significant reduction of postsurgical pain and clinically relevant reduction in opioid consumption.

In a 2017 Cochrane Systematic Review, Hamilton et al. conducted a review of randomised, double-blind, placebo or active-controlled clinical trials in people aged 18 years or over undergoing elective surgery, at any surgical site, if they compared liposomal bupivacaine infiltration at the surgical site with placebo or other type of analgesia. The authors had planned a comparison meta-analysis however there were insufficient data to ensure a clinically meaningful answer. The findings were instead presented as two ‘Summary of Findings’ narratives. The authors concluded that liposomal bupivacaine at the surgical site does appear to reduce postoperative pain compared to placebo; however the limited evidence does not demonstrate superiority to bupivacaine hydrochloride. The authors acknowledge the sparseness of data for outcomes of interest, and a number of studies with a high risk of bias are limitations of this systematic review and limit the confidence in the effect estimates.
Lieblich et al. (2017) conducted a meta-analysis of this randomized, placebo-controlled study, which is the first formal evaluation of liposomal bupivacaine in the setting of dental surgery. The Infiltration Trial in Third Molar Extraction Observing the Analgesic Effect of EXPAREL (INNOVATE), U.S. National Institutes of Health clinical trials identifier NCT02517905 to assess the efficacy, safety, and tolerability of a single administration of liposomal bupivacaine in subjects undergoing bilateral third molar extraction. The results showed that EXPAREL was well tolerated, but was not associated with a significant improvement compared with placebo on any of the outcome measures assessed in the primary efficacy analysis. When the study data were analyzed with subjects representing protocol violations removed, treatment with liposomal bupivacaine resulted in lower least-squares mean cumulative NRS pain intensity scores during the first 48 hours after surgery (primary efficacy measure) compared with placebo. Least-squares mean scores remained significantly lower compared with placebo through 96 hours after surgery, without negatively impacting opioid consumption or subjects’ satisfaction with postsurgical pain control. It is likely that the observed results were confounded by the unexpectedly large number of protocol violations that occurred during the study. The authors concluded that while the results from this study of liposomal bupivacaine for postsurgical analgesia in subjects undergoing bilateral impacted third molar extraction are encouraging, additional investigation in prospective, randomized studies that incorporate clearly defined administration technique, rigorous data collection and protocol compliance will be necessary.

Glenn et al. (2016) conducted a prospective, randomized, double-blind trial to compare an infiltration of bupivacaine with liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, San Diego, CA) for postoperative numbness and pain in symptomatic patients diagnosed with pulp necrosis experiencing moderate to severe preoperative pain. One hundred patients randomly received a 4.0-mL buccal infiltration of either bupivacaine or liposomal bupivacaine after endodontic debridement. For postoperative pain, patients were given ibuprofen/acetaminophen, and they could receive narcotic pain medication if necessary. Patients recorded their level of numbness, pain, and medication use the night of the appointment and over the next 5 days. Success was measured as no or mild postoperative pain and no narcotic use. The results showed the success rate was 29% for the liposomal group and 22% for the bupivacaine group, with no significant difference between the groups. The authors concluded that for these patients, a 4.0-mL infiltration of liposomal bupivacaine did not result in a statistically significant increase in postoperative success compared with an infiltration of 4.0 mL bupivacaine, and did not result in less need for narcotic/opioid pain medication.

Bultema et al. (2016) conducted a study to compare an infiltration of liposomal bupivacaine versus bupivacaine for pain control in untreated, symptomatic irreversible pulpitis. Ninety-five emergency patients received 2% lidocaine with 1:100,000 epinephrine via infiltration or an inferior alveolar nerve block to relieve their initial presenting pain. Patients then randomly received either 4 mL liposomal bupivacaine (13.3 mg/mL) or 4 mL 0.5% bupivacaine with 1:200,000 epinephrine by infiltration. Patients received a diary for the day of the appointment and 3 days post injection to record soft tissue numbness, pain levels, and analgesic (non-narcotic and narcotic) use. The results showed no significant differences (P < .05) between the 2 anesthetic formulations for pain or the use of pain medications. A statistically higher level of soft tissue numbness was found on days 1 to 3 for the liposomal bupivacaine group. The authors concluded that although liposomal bupivacaine had some effect on soft tissue anesthesia, it did not reduce pain to manageable clinical levels in patients presenting with untreated, symptomatic irreversible pulpitis.

While not focused on dentistry or oral surgery, in a 2014 comparative review, Noviasky et al. examines the efficacy of bupivacaine liposomal when compared to conventional bupivacaine with epinephrine using published and unpublished data provided to the FDA by the manufacturer. The authors address efficacy vs. placebo and active control, tolerability, medication safety issues as well as economic considerations. It was concluded that clinical outcomes in active comparator trials have not been improved as evidenced by no statistical difference in pain scores and proportion of patients avoiding use of opioid rescue medication. In trials showing a difference in opioid consumption, some versus placebo, the mean difference was 7 mg morphine equivalents, and the clinical significance of this difference has not been demonstrated. The full review can be found at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062733/pdf/hpj-49-539.pdf.

**Professional Societies**

**American Association of Oral and Maxillofacial Surgeons (AAOMS)**

In a 2017 white paper entitled “Opioid Prescribing: Acute and Postoperative Pain Management,” the AAOMS provides the following considerations for the management of acute and postoperative pain. While oral and maxillofacial surgeons should ultimately make all final prescribing decisions, the recommendations in this AAOMS White Paper are intended to provide direction and serve as a supportive resource.

- A nonsteroidal anti-inflammatory drug administered pre-emptively may decrease the severity of postoperative pain.
- A perioperative corticosteroid (dexamethasone) may limit swelling and decrease postoperative discomfort after third-molar extractions.
- A long-acting local anesthetic (e.g., bupivacaine, etidocaine, liposomal bupivacaine) may delay onset and severity of postoperative pain.
There are extensive drugs and devices used for parenteral medication delivery.

For all drugs (including Exparel), please refer to the following website and search by drug name: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm. (Accessed April 30, 2019)

For devices, please refer to the following website and search by drug name: http://www.accessdata.fda.gov/scripts/cder/cfdocs/cfDA/index.cfm. (Accessed April 30, 2019)

REFERENCES


**POLICY HISTORY/REVISION INFORMATION**

<table>
<thead>
<tr>
<th>Date</th>
<th>Coverage Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/01/2019</td>
<td>• Simplified content</td>
</tr>
<tr>
<td></td>
<td>• Added language to indicate infiltration of sustained release therapeutic drug</td>
</tr>
<tr>
<td></td>
<td>(e.g., Exparel®) is not indicated due to insufficient evidence of efficacy</td>
</tr>
<tr>
<td></td>
<td>• Revised list of coverage Exclusions:</td>
</tr>
<tr>
<td></td>
<td>o Added “procedures that are considered to be Experimental, Investigational or</td>
</tr>
<tr>
<td></td>
<td>Unproven”</td>
</tr>
<tr>
<td></td>
<td>o Removed “drugs/medications, obtainable with or without a prescription,</td>
</tr>
<tr>
<td></td>
<td>unless they are dispensed and utilized in the dental office during the patient</td>
</tr>
<tr>
<td></td>
<td>visit”</td>
</tr>
</tbody>
</table>

**Definitions**

• Added definition of "Experimental, Investigational or Unproven Services ".

**Supporting Information**

• Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information
• Archived previous policy version DCP033.03

**INSTRUCTIONS FOR USE**

This Dental Clinical Policy provides assistance in interpreting UnitedHealthcare standard dental benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard dental plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Dental Clinical Policy is provided for informational purposes. It does not constitute medical advice.